Replies to post #18945 on Ayala Pharmaceuticals Inc (ADXS)

[hovacre]

To defend the comment a bit, though, while you are correct that there is a difference, the vaccine experts at the FDA expect a certain standard from preventative vaccines, which are going to be massively effective.

Cancer vaccines are indeed very different. And in certain cases (see rindopepimut), this has led to some outsized expectations for anticancer vaccines, at least as far as I've heard. It can catch you off guard, and hopefully ADXS will make a clear case for how this approach differs from traditional vaccines.

[terry hallinan]

"There's a big difference between vaccines that prevent and vaccines that treat and sometimes cure."

Care to tell us all the differences? :-)

The first to establish a biotech for the sole purpose of selling a proprietary vaccine adjuvant was Dr. Edgar Ribi, who wanted to call vaccines using his adjuvant theraccines since they would be intended to treat as well as prevent disease.

Before he was killed in a plane crash, Dr. Ribi's adjuvant was licensed to treat surface cancers on race horses.

After his death, Dr. Ribi's invention fell into the hands of clowns - one being Corixa, a favorite of the Seattle Billionaire's Biotech Boys Club and other informal names. Two members of the club were Warren Buffett and Bill Gates. Those of us opposing the sale to Corixa for a rummage sale price were a bit short on funding.

I was asked by a Wall Street Journal reporter why I had so little money in the stock. I asked him how much he would bet against the billionaires. In truth the price had already been reduced to rubble.

When Corixa inevitably went belly up, Dr. Ribi's adjuvant was the only thing of value that anyone wanted. The adjuvant went from shelf-sitting at Corixa to more commodius shelf-sitting at Glaxo but recently there has been new life. Glaxo's record-busting malaria vaccine is powered by the now venerable Ribi adjuvant and a former competitor extracted from the bark of the Chilean soap bark tree.

I beg to differ over the distinguished forebears of Yvonne Paterson's superior adjuvant. Remember Ribi's cured some cancers on horses by its lonesome self and even successfully treated some melanoma in an amateurish mix with ground-up cancer protusions.


Your wording seems to me to downplay the truly novel approach Advaxis has in treating fatal diseases, and thus it's financial potential.

Oh really? Even horse cancers and malaria can be fatal. :-)

Would you rather call Lm a disease vector like Dan rather than a superior powering of treatment and preventive vaccines? :-(

Best, Terry

[hdwrsft]

Ya certainly can't downplay the potential of the NEO approach. That's one heck of a novel approach, imo.